Formulation and Evaluation of Celastrol-Loaded Liposomes

The main purpose of this study was to evaluate the intestinal absorption and the antineoplastic effect of the poorly water-soluble drug celastrol when liposomes were used as oral drug delivery system. Liposomes were prepared by the ethanol-injection method. An optimized liposome formulation composed of phospholipid, cholesterol and Tween-80 resulted in favorable encapsulation efficiency at 98.06 ± 0.94%. Homogeneous and stable particle size of 89.6 ± 7.3 nm and zeta potential of −(87.7 ± 5.8) mV were determined by laser particle size analyzer. Subsequently, the four-site perfusion rat intestinal model revealed that celastrol-loaded liposomes had improved effective permeability compared to the free drug in four intestinal segments (p < 0.05). Moreover, celastrol-loaded liposomes could also inhibit the tumor growth in C57BL/6 mice. These results suggest that liposomes could be a promising perioral carrier for celastrol.

[1]  Yang Di,et al.  Liposome based delivery systems in pancreatic cancer treatment: from bench to bedside. , 2011, Cancer treatment reviews.

[2]  Guang-Biao Zhou,et al.  The Main Anticancer Bullets of the Chinese Medicinal Herb, Thunder God Vine , 2011, Molecules.

[3]  X. Jia,et al.  Role of Intestinal Hydrolase in the Absorption of Prenylated Flavonoids Present in Yinyanghuo , 2011, Molecules.

[4]  X. Jia,et al.  Antioxidant Activities of Total Phenols of Prunella vulgaris L. in Vitro and in Tumor-bearing Mice , 2010, Molecules.

[5]  Xiaoning Zhang,et al.  Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability. , 2010, International journal of pharmaceutics.

[6]  P. Sylvester,et al.  Intestinal Absorption of γ-Tocotrienol Is Mediated by Niemann-Pick C1-Like 1: In Situ Rat Intestinal Perfusion Studies , 2010, Drug Metabolism and Disposition.

[7]  Mingyao Liu,et al.  Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway. , 2010, Cancer research.

[8]  X. Ji,et al.  Celastrol causes apoptosis and cell cycle arrest in rat glioma cells , 2010, Neurological research.

[9]  G. Uzan,et al.  HSP90 inhibitor, celastrol, arrests human monocytic leukemia cell U937 at G0/G1 in thiol-containing agents reversible way , 2010, Molecular Cancer.

[10]  Q. Pankhurst,et al.  Imaging applications of nanotechnology in cancer , 2009, Targeted Oncology.

[11]  T. Lawrence,et al.  Celastrol potentiates radiotherapy by impairment of DNA damage processing in human prostate cancer. , 2009, International journal of radiation oncology, biology, physics.

[12]  M. S. Muthu,et al.  Targeted nanomedicines: effective treatment modalities for cancer, AIDS and brain disorders. , 2009, Nanomedicine.

[13]  K. Mishra,et al.  A simple one-step protocol for preparing small-sized doxorubicin-loaded liposomes. , 2008, Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer.

[14]  S. Krajewski,et al.  Preclinical Studies of Celastrol and Acetyl Isogambogic Acid in Melanoma , 2007, Clinical Cancer Research.

[15]  Young-Soo Hong,et al.  Inhibition of NF-κB activation through targeting IκB kinase by celastrol, a quinone methide triterpenoid , 2006 .

[16]  Di Chen,et al.  Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. , 2006, Cancer research.

[17]  Young-Soo Hong,et al.  Inhibition of NF-kappa B activation through targeting I kappa B kinase by celastrol, a quinone methide triterpenoid. , 2006, Biochemical pharmacology.

[18]  Oselys Rodriguez Justo,et al.  Kanamycin incorporation in lipid vesicles prepared by ethanol injection designed for tuberculosis treatment , 2005, The Journal of pharmacy and pharmacology.

[19]  M. Schubert,et al.  Solvent injection as a new approach for manufacturing lipid nanoparticles--evaluation of the method and process parameters. , 2003, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[20]  A. Domazou,et al.  SIZE DISTRIBUTION OF SPONTANEOUSLY FORMED LIPOSOMES BY THE ALCOHOL INJECTION METHOD , 2002, Journal of liposome research.

[21]  Adrian C. Williams,et al.  Skin delivery of 5‐fluorouracil from ultradeformable and standard liposomes in‐vitro , 2001, The Journal of pharmacy and pharmacology.

[22]  R. Müller,et al.  Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. , 2001, Advanced drug delivery reviews.

[23]  Yechezkel Barenholz,et al.  Liposome application: problems and prospects , 2001 .

[24]  H. Leuenberger,et al.  Large-scale production of liposomes containing monomeric zinc phthalocyanine by controlled dilution of organic solvents. , 1994, Journal of pharmaceutical sciences.

[25]  R. New,et al.  Liposomes : a practical approach , 1990 .

[26]  J. White,et al.  Rapid separation of low molecular weight solutes from liposomes without dilution. , 1978, Analytical biochemistry.

[27]  E. Korn,et al.  Single bilayer liposomes prepared without sonication. , 1973, Biochimica et biophysica acta.